230 related articles for article (PubMed ID: 36927688)
1. Upregulation of acid ceramidase contributes to tumor progression in tuberous sclerosis complex.
Astrinidis A; Li C; Zhang EY; Zhao X; Zhao S; Guo M; Olatoke T; Mattam U; Huang R; Zhang AG; Pitstick L; Kopras EJ; Gupta N; Jandarov R; Smith EP; Fugate E; Lindquist D; Markiewski MM; Karbowniczek M; Wikenheiser-Brokamp KA; Setchell KDR; McCormack FX; Xu Y; Yu JJ
JCI Insight; 2023 May; 8(9):. PubMed ID: 36927688
[TBL] [Abstract][Full Text] [Related]
2. Rapamycin-insensitive up-regulation of adipocyte phospholipase A2 in tuberous sclerosis and lymphangioleiomyomatosis.
Li C; Zhang E; Sun Y; Lee PS; Zhan Y; Guo Y; Osorio JC; Rosas IO; Xu KF; Kwiatkowski DJ; Yu JJ
PLoS One; 2014; 9(10):e104809. PubMed ID: 25347447
[TBL] [Abstract][Full Text] [Related]
3. Urokinase-type plasminogen activator (uPA) is critical for progression of tuberous sclerosis complex 2 (TSC2)-deficient tumors.
Stepanova V; Dergilev KV; Holman KR; Parfyonova YV; Tsokolaeva ZI; Teter M; Atochina-Vasserman EN; Volgina A; Zaitsev SV; Lewis SP; Zabozlaev FG; Obraztsova K; Krymskaya VP; Cines DB
J Biol Chem; 2017 Dec; 292(50):20528-20543. PubMed ID: 28972182
[TBL] [Abstract][Full Text] [Related]
4. Tuberin Regulates Prostaglandin Receptor-Mediated Viability, via Rheb, in mTORC1-Hyperactive Cells.
Li C; Liu X; Liu Y; Zhang E; Medepalli K; Masuda K; Li N; Wikenheiser-Brokamp KA; Osterburg A; Borchers MT; Kopras EJ; Plas DR; Sun J; Franz DN; Capal JK; Mays M; Sun Y; Kwiatkowski DJ; Alayev A; Holz MK; Krueger DA; Siroky BJ; Yu JJ
Mol Cancer Res; 2017 Oct; 15(10):1318-1330. PubMed ID: 28710231
[TBL] [Abstract][Full Text] [Related]
5. Upregulation of 6-phosphofructo-2-kinase (PFKFB3) by hyperactivated mammalian target of rapamycin complex 1 is critical for tumor growth in tuberous sclerosis complex.
Wang Y; Tang S; Wu Y; Wan X; Zhou M; Li H; Zha X
IUBMB Life; 2020 May; 72(5):965-977. PubMed ID: 31958214
[TBL] [Abstract][Full Text] [Related]
6. Rapamycin-independent IGF2 expression in Tsc2-null mouse embryo fibroblasts and human lymphangioleiomyomatosis cells.
Himes BE; Obraztsova K; Lian L; Shumyatcher M; Rue R; Atochina-Vasserman EN; Hur SK; Bartolomei MS; Evans JF; Krymskaya VP
PLoS One; 2018; 13(5):e0197105. PubMed ID: 29758070
[TBL] [Abstract][Full Text] [Related]
7. Targeting SPHK1/S1PR3-regulated S-1-P metabolic disorder triggers autophagic cell death in pulmonary lymphangiomyomatosis (LAM).
Li F; Zhang Y; Lin Z; Yan L; Liu Q; Li Y; Pei X; Feng Y; Han X; Yang J; Zheng F; Li T; Zhang Y; Fu Z; Shao D; Yu J; Li C
Cell Death Dis; 2022 Dec; 13(12):1065. PubMed ID: 36543771
[TBL] [Abstract][Full Text] [Related]
8. Statins in lymphangioleiomyomatosis. Simvastatin and atorvastatin induce differential effects on tuberous sclerosis complex 2-null cell growth and signaling.
Atochina-Vasserman EN; Goncharov DA; Volgina AV; Milavec M; James ML; Krymskaya VP
Am J Respir Cell Mol Biol; 2013 Nov; 49(5):704-9. PubMed ID: 23947572
[TBL] [Abstract][Full Text] [Related]
9. Rapamycin-insensitive up-regulation of MMP2 and other genes in tuberous sclerosis complex 2-deficient lymphangioleiomyomatosis-like cells.
Lee PS; Tsang SW; Moses MA; Trayes-Gibson Z; Hsiao LL; Jensen R; Squillace R; Kwiatkowski DJ
Am J Respir Cell Mol Biol; 2010 Feb; 42(2):227-34. PubMed ID: 19395678
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic Targeting of DGKA-Mediated Macropinocytosis Leads to Phospholipid Reprogramming in Tuberous Sclerosis Complex.
Kovalenko A; Sanin A; Kosmas K; Zhang L; Wang J; Akl EW; Giannikou K; Probst CK; Hougard TR; Rue RW; Krymskaya VP; Asara JM; Lam HC; Kwiatkowski DJ; Henske EP; Filippakis H
Cancer Res; 2021 Apr; 81(8):2086-2100. PubMed ID: 33593821
[TBL] [Abstract][Full Text] [Related]
11. mTORC1-mediated downregulation of COX2 restrains tumor growth caused by TSC2 deficiency.
Li H; Jin F; Jiang K; Ji S; Wang L; Ni Z; Chen X; Hu Z; Zhang H; Liu Y; Qin Y; Zha X
Oncotarget; 2016 May; 7(19):28435-47. PubMed ID: 27078846
[TBL] [Abstract][Full Text] [Related]
12. Prevention of alveolar destruction and airspace enlargement in a mouse model of pulmonary lymphangioleiomyomatosis (LAM).
Goncharova EA; Goncharov DA; Fehrenbach M; Khavin I; Ducka B; Hino O; Colby TV; Merrilees MJ; Haczku A; Albelda SM; Krymskaya VP
Sci Transl Med; 2012 Oct; 4(154):154ra134. PubMed ID: 23035046
[TBL] [Abstract][Full Text] [Related]
13. Rapamycin-resistant poly (ADP-ribose) polymerase-1 overexpression is a potential therapeutic target in lymphangioleiomyomatosis.
Sun Y; Gallacchi D; Zhang EY; Reynolds SB; Robinson L; Malinowska IA; Chiou TT; Pereira AM; Li C; Kwiatkowski DJ; Lee PS; Yu JJ
Am J Respir Cell Mol Biol; 2014 Dec; 51(6):738-49. PubMed ID: 24874429
[TBL] [Abstract][Full Text] [Related]
14. Rapamycin weekly maintenance dosing and the potential efficacy of combination sorafenib plus rapamycin but not atorvastatin or doxycycline in tuberous sclerosis preclinical models.
Lee N; Woodrum CL; Nobil AM; Rauktys AE; Messina MP; Dabora SL
BMC Pharmacol; 2009 Apr; 9():8. PubMed ID: 19368729
[TBL] [Abstract][Full Text] [Related]
15. Uterine-specific loss of Tsc2 leads to myometrial tumors in both the uterus and lungs.
Prizant H; Sen A; Light A; Cho SN; DeMayo FJ; Lydon JP; Hammes SR
Mol Endocrinol; 2013 Sep; 27(9):1403-14. PubMed ID: 23820898
[TBL] [Abstract][Full Text] [Related]
16. Rapamycin-upregulated miR-29b promotes mTORC1-hyperactive cell growth in TSC2-deficient cells by downregulating tumor suppressor retinoic acid receptor β (RARβ).
Liu HJ; Lam HC; Baglini CV; Nijmeh J; Cottrill AA; Chan SY; Henske EP
Oncogene; 2019 Dec; 38(49):7367-7383. PubMed ID: 31420607
[TBL] [Abstract][Full Text] [Related]
17. Translatome analysis of tuberous sclerosis complex 1 patient-derived neural progenitor cells reveals rapamycin-dependent and independent alterations.
Aksoylu IS; Martin P; Robert F; Szkop KJ; Redmond NE; Bhattacharyya S; Wang J; Chen S; Beauchamp RL; Nobeli I; Pelletier J; Larsson O; Ramesh V
Mol Autism; 2023 Oct; 14(1):39. PubMed ID: 37880800
[TBL] [Abstract][Full Text] [Related]
18. Alterations in Polyamine Metabolism in Patients With Lymphangioleiomyomatosis and Tuberous Sclerosis Complex 2-Deficient Cells.
Tang Y; El-Chemaly S; Taveira-Dasilva A; Goldberg HJ; Bagwe S; Rosas IO; Moss J; Priolo C; Henske EP
Chest; 2019 Dec; 156(6):1137-1148. PubMed ID: 31299246
[TBL] [Abstract][Full Text] [Related]
19. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors.
Woodrum C; Nobil A; Dabora SL
J Transl Med; 2010 Feb; 8():14. PubMed ID: 20146790
[TBL] [Abstract][Full Text] [Related]
20. TSC2-deficient tumors have evidence of T cell exhaustion and respond to anti-PD-1/anti-CTLA-4 immunotherapy.
Liu HJ; Lizotte PH; Du H; Speranza MC; Lam HC; Vaughan S; Alesi N; Wong KK; Freeman GJ; Sharpe AH; Henske EP
JCI Insight; 2018 Apr; 3(8):. PubMed ID: 29669930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
